Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
Reviva Pharmaceuticals (NASDAQ: RVPH) said CEO Laxminarayan Bhat, PhD, will join a Key Opinion Leader webinar and fireside chat hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The session will include KOLs Dr. Larry Ereshefsky and Dr. Mark Opler, focus on the unmet need and treatment landscape for schizophrenia, and discuss phase 3 clinical data for Reviva’s lead candidate brilaroxazine. The conversation will be moderated by James Molloy of A.G.P. A replay will be posted in Reviva’s investor relations section after the event.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha comunicato che il CEO Laxminarayan Bhat, PhD, parteciperà a un webinar di Leader di opinione chiave e a un colloquio informale ospitato da A.G.P./Alliance Global Partners il 10 ottobre 2025 alle 11:00 ET.
La sessione vedrà la partecipazione dei KOL Dr. Larry Ereshefsky e Dr. Mark Opler, si concentrerà sull'intervento non soddisfatto e sul panorama di trattamento per la schizofrenia e discuterà i dati clinici di fase 3 per il candidato principale di Reviva, brilaroxazine. Il dibattito sarà moderato da James Molloy di A.G.P. Una replica sarà pubblicata nella sezione delle relazioni con gli investitori di Reviva dopo l'evento.
Reviva Pharmaceuticals (NASDAQ: RVPH) dijo que el CEO Laxminarayan Bhat, PhD, participará en un webinar de Líderes de Opinión y charla junto a la chimenea organizado por A.G.P./Alliance Global Partners el 10 de octubre de 2025 a las 11:00 AM ET.
La sesión contará con KOLs Dr. Larry Ereshefsky y Dr. Mark Opler, se centrará en la necesidad no atendida y el panorama de tratamiento para la esquizofrenia, y discutirá datos clínicos de fase 3 para el candidato principal de Reviva, brilaroxazine. La conversación será moderada por James Molloy de A.G.P. Se publicará una repetición en la sección de relaciones con inversores de Reviva después del evento.
Reviva Pharmaceuticals (NASDAQ: RVPH)의 CEO 라크시마나얀 바트 박사(PhD)가 A.G.P./Alliance Global Partners가 주최하는 Key Opinion Leader webinar and fireside chat에 참여할 예정이라고 말했다. 행사일은 2025년 10월 10일 동부시간 오전 11:00입니다.
세션에는 KOL Dr. Larry Ereshefsky 및 Dr. Mark Opler가 참여하고, 조현병의 미해결 필요 및 치료 현황에 초점을 맞추며 Reviva의 주력 후보물질인 brilaroxazine의 3상 임상 데이터도 논의합니다. 대담은 A.G.P.의 James Molloy가 진행합니다. 이벤트 이후 Reviva의 투자자 관계 섹션에 리플레이가 게시될 예정입니다.
Reviva Pharmaceuticals (NASDAQ: RVPH) a déclaré que le PDG Laxminarayan Bhat, PhD, participera à un webinaire de leaders d'opinion et à un chat informel organisé par A.G.P./Alliance Global Partners le 10 octobre 2025 à 11h00 ET.
La séance réunira des KOLs Dr. Larry Ereshefsky et Dr. Mark Opler, se concentrera sur le besoin non satisfait et le paysage thérapeutique de la schizophrénie et discutera des données cliniques de phase 3 pour le candidat phare de Reviva, brilaroxazine. La conversation sera modérée par James Molloy d'A.G.P. Une rediffusion sera publiée dans la section relations avec les investisseurs de Reviva après l'événement.
Reviva Pharmaceuticals (NASDAQ: RVPH) meldete, dass CEO Laxminarayan Bhat, PhD, an einem Key Opinion Leader-Webinar und Fireside-Chat teilnimmt, das von A.G.P./Alliance Global Partners am 10. Oktober 2025 um 11:00 Uhr ET ausgerichtet wird.
Die Sitzung wird KOLs Dr. Larry Ereshefsky und Dr. Mark Opler umfassen, sich auf den nicht gedeckten Bedarf und die Behandlungslage bei Schizophrenie konzentrieren und Daten der Phase-3-Studie für Revivas Leitkandidaten brilaroxazine diskutieren. Das Gespräch wird von James Molloy von A.G.P. moderiert. Eine Wiederholung wird nach der Veranstaltung im Bereich Investor Relations von Reviva veröffentlicht.
Reviva Pharmaceuticals (NASDAQ: RVPH) قالت إن المدير التنفيذي ليكسنارايان بات، دكتوراه، سيشارك في وبينار لقيادات الرأي الكبرى ومحادثة Fireside تستضيفها A.G.P./Alliance Global Partners في 10 أكتوبر 2025 الساعة 11:00 صباحاً بتوقيت شرق الولايات المتحدة.
ستضم الجلسة KOLs الدكتور لاري إريشفسكي والدكتور مارك أوبلر، وستركز على الاحتياج غير الملبّى ومنظور علاج الفصام، وستناقش بيانات المرحلة 3 الخاصة بالمرشح الرئيسي لشركة Reviva brilaroxazine. ستدار المحادثة من قبل جيمس مولوي من A.G.P. وسيتم نشر إعادة البث في قسم علاقات المستثمرين بشركة Reviva بعد الحدث.
Reviva Pharmaceuticals (NASDAQ: RVPH) 表示 CEO Laxminarayan Bhat, PhD，将参加由 A.G.P./Alliance Global Partners 主办的 关键意见领袖网络研讨会及炉边谈话，时间定于 2025年10月10日美国东部时间上午11:00。
该会议将邀请 KOLs Dr. Larry Ereshefsky 与 Dr. Mark Opler，聚焦于 精神分裂症的未满足需求与治疗现状，并讨论 Reviva 的主要候选药物 brilaroxazine 的 III 期临床数据。对话将由 A.G.P. 的 James Molloy 主持。事件结束后，Reviva 的投资者关系板块将发布回放。
- None.
- None.
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The webinar will feature an in-depth Fireside Chat with RVPH CEO Laxminarayan Bhat, PhD, and KOLs including Dr. Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research) and Dr. Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). The unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia and the phase 3 clinical data of Reviva’s lead drug candidate brilaroxazine for schizophrenia will be discussed. The conversation will be moderated by A.G.P./Alliance Global Partners' James Molloy.
To register for the event, please click here. A replay of the webinar will be accessible in the investors section of Reviva’s website following the event.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When is Reviva (RVPH) presenting in the A.G.P. webinar?
What topics will Reviva (RVPH) cover in the October 10, 2025 webinar?
Who are the key speakers alongside Reviva (RVPH) CEO in the webinar?
How can investors register for the Reviva (RVPH) webinar on October 10, 2025?
Will there be a replay of the Reviva (RVPH) KOL webinar if I miss the live session?
Will the Reviva (RVPH) webinar include details on brilaroxazine phase 3 results?
